33,915 Shares in CryoPort, Inc. $CYRX Bought by Ieq Capital LLC

Ieq Capital LLC purchased a new stake in shares of CryoPort, Inc. (NASDAQ:CYRX - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 33,915 shares of the company's stock, valued at approximately $206,000. Ieq Capital LLC owned 0.07% of CryoPort as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. grew its stake in shares of CryoPort by 148.7% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company's stock valued at $28,000 after purchasing an additional 2,120 shares during the period. Lazard Asset Management LLC bought a new stake in shares of CryoPort in the 4th quarter valued at approximately $51,000. SBI Securities Co. Ltd. grew its stake in shares of CryoPort by 548,750.0% in the 1st quarter. SBI Securities Co. Ltd. now owns 10,977 shares of the company's stock valued at $67,000 after purchasing an additional 10,975 shares during the period. CWM LLC grew its stake in shares of CryoPort by 1,437.0% in the 1st quarter. CWM LLC now owns 11,328 shares of the company's stock valued at $69,000 after purchasing an additional 10,591 shares during the period. Finally, GAMMA Investing LLC grew its stake in shares of CryoPort by 4,434.6% in the 1st quarter. GAMMA Investing LLC now owns 14,556 shares of the company's stock valued at $89,000 after purchasing an additional 14,235 shares during the period. 92.90% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

CYRX has been the topic of several recent analyst reports. Stephens initiated coverage on CryoPort in a report on Tuesday, July 22nd. They issued an "overweight" rating and a $13.00 target price on the stock. KeyCorp raised CryoPort from a "sector weight" rating to an "overweight" rating and set a $15.00 target price on the stock in a report on Wednesday, August 6th. BTIG Research reduced their target price on CryoPort from $13.00 to $10.00 and set a "buy" rating on the stock in a report on Monday, July 7th. Leerink Partnrs raised CryoPort from a "hold" rating to a "strong-buy" rating in a report on Wednesday, August 6th. Finally, Leerink Partners raised CryoPort from a "market perform" rating to an "outperform" rating and set a $16.00 target price on the stock in a report on Wednesday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, CryoPort presently has a consensus rating of "Buy" and a consensus price target of $12.00.

Insider Buying and Selling

In other news, Director Robert J. Hariri sold 5,000 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $8.60, for a total value of $43,000.00. Following the transaction, the director owned 26,275 shares of the company's stock, valued at $225,965. This represents a 15.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Robert Stefanovich sold 9,300 shares of the stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $8.67, for a total value of $80,631.00. Following the completion of the transaction, the chief financial officer directly owned 207,213 shares in the company, valued at approximately $1,796,536.71. This trade represents a 4.30% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 425,037 shares of company stock worth $2,921,501. Company insiders own 10.00% of the company's stock.

CryoPort Trading Up 2.1%

Shares of CYRX stock traded up $0.20 during trading hours on Thursday, reaching $9.79. The company had a trading volume of 230,428 shares, compared to its average volume of 538,783. The company has a 50 day moving average of $8.17 and a 200 day moving average of $6.86. The company has a debt-to-equity ratio of 0.39, a current ratio of 16.24 and a quick ratio of 15.47. The firm has a market cap of $490.19 million, a price-to-earnings ratio of 7.36 and a beta of 1.62. CryoPort, Inc. has a 1-year low of $4.58 and a 1-year high of $10.46.

CryoPort (NASDAQ:CYRX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.09). The company had revenue of $45.45 million during the quarter, compared to analyst estimates of $41.74 million. CryoPort had a net margin of 37.21% and a negative return on equity of 9.79%. CryoPort has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that CryoPort, Inc. will post -0.99 EPS for the current year.

CryoPort Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.